Alberto Martini

List of Publications by Year
in descending order

386 papers	33,278 citations	2802 94 h-index	5120 166 g-index
402 all docs	402 docs citations	402 times ranked	19954 citing authors

#	Article	IF	Citations
1	The obesity paradox in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 472-478.	3.9	15
2	Long-term efficacy and safety of canakinumab in patients with mevalonate kinase deficiency: results from the randomised Phase 3 CLUSTER trial. Rheumatology, 2022, 61, 2088-2094.	1.9	2
3	Juvenile idiopathic arthritis. Nature Reviews Disease Primers, 2022, 8, 5.	30.5	90
4	Strain Modal Testing with Fiber Bragg Gratings for Automotive Applications. Sensors, 2022, 22, 946.	3.8	14
5	Metastasis Within Three Years from Radical Nephroureterectomy as a Potential Surrogate for Overall Survival. Clinical Genitourinary Cancer, 2022, 20, 389.e1-389.e7.	1.9	1
6	Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancerâ€"Current State and Future Perspectives. Cancers, 2022, 14, 147.	3.7	2
7	Adjuvant immunotherapy in patients with highâ€risk muscleâ€invasive urothelial carcinoma: The potential impact of informative censoring. Cancer, 2022, 128, 2892-2897.	4.1	6
8	Tofacitinib for juvenile idiopathic arthritis â€" Authors' reply. Lancet, The, 2022, 399, 1866.	13.7	0
9	Acute kidney injury and functional outcomes after partial nephrectomy. International Journal of Urology, 2022, 29, 1243-1244.	1.0	1
10	Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Openâ€Label, Randomized Study. Arthritis and Rheumatology, 2021, 73, 336-346.	5.6	23
11	How to Select the Optimal Candidates for Renal Mass Biopsy. European Urology Oncology, 2021, 4, 506-509.	5.4	10
12	Efficacy and Safety of Tocilizumab for Polyarticularâ€Course Juvenile Idiopathic Arthritis in the Openâ€Label Twoâ€Year Extension of a Phase III Trial. Arthritis and Rheumatology, 2021, 73, 530-541.	5.6	16
13	Defining Risk Categories for a Significant Decline in Estimated Glomerular Filtration Rate After Robotic Partial Nephrectomy: Implications for Patient Follow-up. European Urology Oncology, 2021, 4, 498-501.	5.4	11
14	Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2021, 48, 1073-1081.	2.0	3
15	Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. Rheumatology, 2021, 60, 4495-4507.	1.9	15
16	Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. Rheumatology, 2021, 60, 4568-4580.	1.9	18
17	Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data. Prostate Cancer and Prostatic Diseases, 2021, 24, 743-749.	3.9	4
18	Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nature Reviews Rheumatology, 2021, 17, 257-269.	8.0	52

#	Article	IF	Citations
19	Re: Mathieu Rouanne, Dean F. Bajorin, Raquibul Hannan, et al. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. Eur Urol Oncol 2020;3:728â€“38. European Urology Oncology, 2021, 4, 336.	5.4	0
20	Strain Modal Testing with Fiber Bragg Grating Sensors of Composite Components for Automotive Applications. , 2021, , .		1
21	Estimation of the braking torque for MotoGP class motorcycles with carbon braking systems through machine learning algorithms. , 2021, , .		1
22	â€œTo Randomize, or Not to Randomize, That is the Questionâ€• Arthritis and Rheumatology, 2021, 73, 1776-1779.	5.6	2
23	Evidence-based Urology: Surrogate Endpoints â€“ Pro. European Urology Focus, 2021, 7, 1217-1218.	3.1	3
24	Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet, The, 2021, 398, 1984-1996.	13.7	79
25	Bladder Cancer (NMIBC) in a population-based cohort from Stockholm County with long-term follow-up; A comparative analysis of prediction models for recurrence and progression, including external validation of the updated 2021 E.A.U. model. Urologic Oncology: Seminars and Original Investigations, 2021, , .	1.6	6
26	The Role of Prior Bladder Cancer on Recurrence in Patients Treated with Radical Nephroureterectomy. Clinical Genitourinary Cancer, 2021, , .	1.9	3
27	Growth and Puberty in Juvenile Dermatomyositis: A Longitudinal Cohort Study. Arthritis Care and Research, 2020, 72, 265-273.	3.4	7
28	Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Sevenâ€•Year Interim Results. Arthritis Care and Research, 2020, 72, 1420-1430.	3.4	17
29	The natural history of untreated muscleâ€•invasive bladder cancer. BJU International, 2020, 125, 270-275.	2.5	72
30	A novel knock-in mouse model of cryopyrin-associated periodic syndromes with development of amyloidosis: Therapeutic efficacy of proton pump inhibitors. Journal of Allergy and Clinical Immunology, 2020, 145, 368-378.e13.	2.9	14
31	Experimental Characterization of a High-Damping Viscoelastic Material Enclosed in Carbon Fiber Reinforced Polymer Components. Applied Sciences (Switzerland), 2020, 10, 6193.	2.5	15
32	Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate. RMD Open, 2020, 6, e001208.	3.8	13
33	Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Openâ€•Label, Activeâ€•Treatment Extension Study. Arthritis and Rheumatology, 2020, 72, 2147-2158.	5.6	21
34	Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Annals of the Rheumatic Diseases, 2020, 79, 1340-1348.	0.9	106
35	Functional Ability and Healthâ€•Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2020, 73, 1264-1274.	3.4	4
36	RHAPSODY: Rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1Î± and interleukin-1Î² trap, in patients with recurrent pericarditis. American Heart Journal, 2020, 228, 81-90.	2.7	43

#	Article	IF	Citations
37	Contemporary Techniques of Prostate Dissection for Robot-assisted Prostatectomy. European Urology, 2020, 78, 583-591.	1.9	78
38	Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis. Paediatric Drugs, 2020, 22, 653-672.	3.1	13
39	Fused Omics Data Models Reveal Gut Microbiome Signatures Specific of Inactive Stage of Juvenile Idiopathic Arthritis in Pediatric Patients. Microorganisms, 2020, 8, 1540.	3.6	5
40	Virtual Testing of Counterbalance Forklift Trucks: Implementation and Experimental Validation of a Numerical Multibody Model. Machines, 2020, 8, 26.	2.2	13
41	Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial. Prostate Cancer and Prostatic Diseases, 2020, 23, 638-645.	3.9	9
42	The Extended Polydimensional Immunome Characterization (EPIC) web-based reference and discovery tool for cytometry data. Nature Biotechnology, 2020, 38, 679-684.	17.5	25
43	Kawasaki disease or Kawasaki syndrome?. Annals of the Rheumatic Diseases, 2020, 79, 993-995.	0.9	22
44	Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2â€“5â€‰years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept. Pediatric Rheumatology, 2020, 18, 19.	2.1	15
45	Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. Arthritis Research and Therapy, 2020, 22, 71.	3.5	25
46	Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 684.e9-684.e15.	1.6	8
47	Multibody Models and Simulations to Assess the Stability of Counterbalance Forklift Trucks. Computational Methods in Applied Sciences (Springer), 2020, , 526-533.	0.3	1
48	Static Balancing of an Exechon-Like Parallel Mechanism. Lecture Notes in Mechanical Engineering, 2020, , 310-321.	0.4	0
49	Kinematics optimization of the polishing process of large-sized ceramic slabs. International Journal of Advanced Manufacturing Technology, 2019, 103, 1325-1336.	3.0	13
50	Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2019, 78, 1357-1362.	0.9	74
51	Conditionally Reprogrammed Patient-derived Cells: A Step Forward Towards Personalized Medicine?. European Urology, 2019, 76, 435-436.	1.9	6
52	Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis. Rheumatology, 2019, 58, 1196-1205.	1.9	10
53	The European network for care of children with paediatric rheumatic diseases: care across borders. Rheumatology, 2019, 58, 1188-1195.	1.9	15
54	An Approach for Predicting the Specific Fuel Consumption of Dual-Fuel Two-Stroke Marine Engines. Journal of Marine Science and Engineering, 2019, 7, 20.	2.6	11

#	Article	IF	Citations
55	Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial. Arthritis Research and Therapy, 2019, 21, 125.	3.5	31
56	Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscleâ€invasive bladder cancer. Cancer, 2019, 125, 3155-3163.	4.1	32
57	The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients. Pediatric Rheumatology, 2019, 17, 24.	2.1	14
58	Predicting acute kidney injury after robot-assisted partial nephrectomy: Implications for patient selection and postoperative management. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 445-451.	1.6	24
59	Classification criteria for autoinflammatory recurrent fevers. Annals of the Rheumatic Diseases, 2019, 78, 1025-1032.	0.9	300
60	A transcriptomic signature of tertiary Gleason 5 predicts worse clinicopathological outcome. BJU International, 2019, 124, 155-162.	2.5	7
61	Pathological downstaging as a novel endpoint for the development of neoadjuvant chemotherapy for upper tract urothelial carcinoma. BJU International, 2019, 124, 665-671.	2.5	34
62	Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. The Lancet Child and Adolescent Health, 2019, 3, 255-263.	5.6	120
63	Algorithm for the static balancing of serial and parallel mechanisms combining counterweights and springs: Generation, assessment and ranking of effective design variants. Mechanism and Machine Theory, 2019, 137, 336-354.	4.5	34
64	Evaluation of Cause of Death After Radical Cystectomy for Patients With Bladder Cancer: The Impact of Age at the Time of Surgery. Clinical Genitourinary Cancer, 2019, 17, e541-e548.	1.9	6
65	SAT0024â€…TRANSCRIPTOMIC PROFILING OF THE MICROENVIRONMENT DRIVEN RE-SHAPING OF PATHOGENIC CIRCULATORY AND SYNOVIAL HLA-DR+ CD4 T SUBSETS IN ACTIVE JUVENILE IDIOPATHIC ARTHRITIC PATIENTS. , 2019, , .		0
66	THU0517â€…THE LONGITUDINAL EUROFEVER PROJECT: AN UPDATE ON ENROLLMENT. , 2019, , .		0
67	OP0258â€…LESSON FROM EUROFEVER REGISTRY AFTER THE FIRST TEN YEARS OF ENROLLMENT. , 2019, , .		0
68	THU0516â€…LONG-TERM SAFETY OF SUBCUTANEOUS TOCILIZUMAB ADMINISTRATION IN SYSTEMIC AND POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS. , 2019, , .		0
69	Are there new targets for juvenile idiopathic arthritis?. Seminars in Arthritis and Rheumatism, 2019, 49, S11-S13.	3.4	12
70	Clinical trials in children and adolescents with systemic lupus erythematosus: methodological aspects, regulatory landscape and future opportunities. Annals of the Rheumatic Diseases, 2019, 78, 162-170.	0.9	13
71	An updated approach to incremental nerve sparing for robotâ€assisted radical prostatectomy. BJU International, 2019, 124, 103-108.	2.5	21
72	Microbiome Analytics of the Gut Microbiota in Patients With Juvenile Idiopathic Arthritis: A Longitudinal Observational Cohort Study. Arthritis and Rheumatology, 2019, 71, 1000-1010.	5.6	44

#	Article	IF	Citations
73	An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptorâ€"associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome. Journal of Rheumatology, 2019, 46, 429-436.	2.0	16
74	Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus. Journal of Rheumatology, 2019, 46, 190-197.	2.0	318
75	Static stress analysis of suspension systems for a solar-powered car. FME Transactions, 2019, 47, 70-75.	1.4	19
76	Assessment of Wall Vibrations in the Long Pipe Facility at CICLoPE. Springer Proceedings in Physics, 2019, , 203-208.	0.2	0
77	Subcutaneous Abatacept in Patients With Polyarticularâ€Course Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2018, 70, 1144-1154.	5.6	45
78	Development and internal validation of a sideâ€specific, multiparametric magnetic resonance imagingâ€based nomogram for the prediction of extracapsular extension of prostate cancer. BJU International, 2018, 122, 1025-1033.	2.5	86
79	An international delphi survey for the definition of the variables for the development of new classification criteria for periodic fever aphtous stomatitis pharingitis cervical adenitis (PFAPA). Pediatric Rheumatology, 2018, 16, 27.	2.1	21
80	Re: Serra-Aracil et al.: The Place of Transanal Endoscopic Surgery in the Treatment of Rectourethral Fistula (Urology 2018;111:139-144). Urology, 2018, 115, 193-194.	1.0	2
81	The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry. Rheumatology, 2018, 57, 1203-1211.	1.9	105
82	IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukinâ€1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2018, 70, 1319-1330.	5.6	40
83	Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism. Internal and Emergency Medicine, 2018, 13, 475-489.	2.0	48
84	The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 251-258.	3.0	2
85	Current and future perspectives in the management of juvenile idiopathic arthritis. The Lancet Child and Adolescent Health, 2018, 2, 360-370.	5.6	39
86	Development and Testing of a Hybrid Measure of Muscle Strength in Juvenile Dermatomyositis for Use in Routine Care. Arthritis Care and Research, 2018, 70, 1312-1319.	3.4	19
87	Preface. Rheumatology International, 2018, 38, 1-3.	3.0	6
88	Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology. Rheumatology International, 2018, 38, 5-17.	3.0	74
89	Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Annals of the Rheumatic Diseases, 2018, 77, 21-29.	0.9	96
90	Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative. Annals of the Rheumatic Diseases, 2018, 77, 319-327.	0.9	9

#	Article	IF	Citations
91	Autocorrelation Analysis of Vibro-Acoustic Signals Measured in a Test Field for Water Leak Detection. Applied Sciences (Switzerland), 2018, 8, 2450.	2.5	55
92	Educational initiatives and training for paediatric rheumatology in Europe. Pediatric Rheumatology, 2018, 16, 77.	2.1	10
93	Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. Arthritis Research and Therapy, 2018, 20, 285.	3.5	71
94	Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Annals of the Rheumatic Diseases, 2018, 77, 1710-1719.	0.9	79
95	A Nomogram to Predict Significant Estimated Glomerular Filtration Rate Reduction After Robotic Partial Nephrectomy. European Urology, 2018, 74, 833-839.	1.9	76
96	The role of imaging in juvenile idiopathic arthritis. Expert Review of Clinical Immunology, 2018, 14, 681-694.	3.0	17
97	Prediction of inactive disease in juvenile idiopathic arthritis: a multicentre observational cohort study. Rheumatology, 2018, 57, 1752-1760.	1.9	15
98	Molecular mechanisms of autophagic memory in pathogenic T cells in human arthritis. Journal of Autoimmunity, 2018, 94, 90-98.	6.5	11
99	In silico validation of the Autoinflammatory Disease Damage Index. Annals of the Rheumatic Diseases, 2018, 77, 1599-1605.	0.9	27
100	Recurrent pericarditis: still idiopathic? The pros and cons of a well-honoured term. Internal and Emergency Medicine, 2018, 13, 839-844.	2.0	48
101	Patientâ€™s experiences with the care for juvenile idiopathic arthritis across Europe. Pediatric Rheumatology, 2018, 16, 10.	2.1	14
102	Effect of the Inclusion of the Metacarpophalangeal Joints on the Wrist Magnetic Resonance Imaging Scoring System in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2018, 45, 1581-1587.	2.0	4
103	Gravity compensation of a 6-UPS parallel kinematics machine tool through elastically balanced constant-force generators. FME Transactions, 2018, 46, 10-16.	1.4	21
104	Murine Ranklâˆ’/âˆ’ Mesenchymal Stromal Cells Display an Osteogenic Differentiation Defect Improved by a RANKL-Expressing Lentiviral Vector. Stem Cells, 2017, 35, 1365-1377.	3.2	18
105	Editorial comment to: Ileal versus sigmoid neobladder as bladder substitute after radical cystectomy for bladder cancer: A meta-analysis. International Journal of Surgery, 2017, 37, 13-14.	2.7	2
106	EXTL3 mutations cause skeletal dysplasia, immune deficiency, and developmental delay. Journal of Experimental Medicine, 2017, 214, 623-637.	8.5	76
107	Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial. Lancet, The, 2017, 389, 909-916.	13.7	52
108	Development of the autoinflammatory disease damage index (ADDI). Annals of the Rheumatic Diseases, 2017, 76, 821-830.	0.9	68

#	Article	IF	Citations
109	TCR repertoire sequencing identifies synovial Treg cell clonotypes in the bloodstream during active inflammation in human arthritis. Annals of the Rheumatic Diseases, 2017, 76, 435-441.	0.9	64
110	Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. Annals of the Rheumatic Diseases, 2017, 76, 173-178.	0.9	96
111	EULAR/PReS standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases. Annals of the Rheumatic Diseases, 2017, 76, 639-646.	0.9	157
112	Resolution of pericardial constriction with anakinra; possible role of C reactive protein. International Journal of Cardiology, 2017, 234, 150.	1.7	0
113	ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study. Annals of the Rheumatic Diseases, 2017, 76, 1648-1656.	0.9	199
114	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2017, 69, 911-923.	5.6	59
115	Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. Annals of the Rheumatic Diseases, 2017, 76, 906-913.	0.9	123
116	Extrapolation or controlled trials in paediatrics: the current dilemma. Archives of Disease in Childhood, 2017, 102, 949-951.	1.9	10
117	Cryopyrin-associated Periodic Syndromes in Italian Patients: Evaluation of the Rate of Somatic NLRP3 Mosaicism and Phenotypic Characterization. Journal of Rheumatology, 2017, 44, 1667-1673.	2.0	28
118	Long-term complications arising from bowel interposition in the urinary tract. International Journal of Surgery, 2017, 44, 278-280.	2.7	17
119	Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. Journal of Pediatrics, 2017, 189, 72-78.e3.	1.8	50
120	Vibroacoustic Measurements for Detecting Water Leaks in Buried Small-Diameter Plastic Pipes. Journal of Pipeline Systems Engineering and Practice, 2017, 8, .	1.6	46
121	How I treat juvenile idiopathic arthritis: A state of the art review. Autoimmunity Reviews, 2017, 16, 1008-1015.	5.8	31
122	Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. Arthritis Research and Therapy, 2017, 19, 13.	3.5	49
123	Temporomandibular Joint Involvement in Association With Quality of Life, Disability, and High Disease Activity in Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2017, 69, 677-686.	3.4	52
124	2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteriaâ€"methodological aspects. Rheumatology, 2017, 56, 1884-1893.	1.9	33
125	Leak Detection in Water-Filled Small-Diameter Polyethylene Pipes by Means of Acoustic Emission Measurements. Applied Sciences (Switzerland), 2017, 7, 2.	2.5	96
126	Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. Pediatric Rheumatology, 2017, 15, 86.	2.1	64

#	Article	IF	Citations
127	A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry. Orphanet Journal of Rare Diseases, 2017, 12, 167.	2.7	52
128	CD70 Deficiency due to a Novel Mutation in a Patient with Severe Chronic EBV Infection Presenting As a Periodic Fever. Frontiers in Immunology, 2017, 8, 2015.	4.8	31
129	STRUCTURAL AND ELASTODYNAMIC ANALYSIS OF ROTARY TRANSFER MACHINES BY FINITE ELEMENT MODEL. Journal of the Serbian Society for Computational Mechanics, 2017, 11, 1-16.	0.4	13
130	Overview of Juvenile Idiopathic Arthritis. , 2017, , 201-218.		0
131	The PRINTO juvenile dermatomyositis trial â€“ Authors' reply. Lancet, The, 2016, 387, 2601.	13.7	0
132	Delineating the Application of Ultrasound in Detecting Synovial Abnormalities of the Subtalar Joint in Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2016, 68, 1346-1353.	3.4	22
133	A Metaâ€Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2016, 68, 1540-1550.	5.6	11
134	Anakinra. Journal of Cardiovascular Medicine, 2016, 17, 256-262.	1.5	54
135	The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry. Arthritis and Rheumatology, 2016, 68, 2795-2805.	5.6	168
136	Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. Pediatric Rheumatology, 2016, 14, 68.	2.1	35
137	Recurrent pericarditis in children and adolescents. Journal of Cardiovascular Medicine, 2016, 17, 707-712.	1.5	61
138	Upgrade of an automated line for plastic cap manufacture based on experimental vibration analysis. Case Studies in Mechanical Systems and Signal Processing, 2016, 3, 28-33.	1.4	13
139	Clinical Characteristics of Patients Carrying the Q703K Variant of the NLRP3 Gene: A 10-year Multicentric National Study. Journal of Rheumatology, 2016, 43, 1093-1100.	2.0	31
140	Disease activity accounts for long-term efficacy of IL-1 blockers in pyogenic sterile arthritis pyoderma gangrenosum and severe acne syndrome. Rheumatology, 2016, 55, 1325-1335.	1.9	48
141	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2016, 68, 566-576.	5.6	427
142	Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab. Arthritis and Rheumatology, 2016, 68, 218-228.	5.6	103
143	Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence. JAMA - Journal of the American Medical Association, 2016, 316, 1906.	7.4	242
144	Autoinflammatory syndromes: rare diseases with important implications in quality of life. Revista Brasileira De Reumatologia, 2016, 56, 1.	0.7	0

#	Article	IF	Citations
145	Reviewer acknowledgement 2015. Pediatric Rheumatology, 2016, 14, .	2.1	0
146	Inflammation and Its Mediators. , 2016, , 14-32.e2.		3
147	Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. RMD Open, 2016, 2, e000161.	3.8	57
148	A circulating reservoir of pathogenic-like CD4⁺T cells shares a genetic and phenotypic signature with the inflamed synovial micro-environment. Annals of the Rheumatic Diseases, 2016, 75, 459-465.	0.9	62
149	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 481-489.	0.9	338
150	Conservative Treatment of Serous Borderline Paratesticular Tumor in a Pediatric Patient. Urology, 2016, 89, 123-125.	1.0	6
151	Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis. Journal of Rheumatology, 2016, 43, 816-824.	2.0	46
152	Performance of Different Diagnostic Criteria for Familial Mediterranean Fever in Children with Periodic Fevers: Results from a Multicenter International Registry. Journal of Rheumatology, 2016, 43, 154-160.	2.0	52
153	Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet, The, 2016, 387, 671-678.	13.7	168
154	Next-generation sequencing and its initial applications for molecular diagnosis of systemic auto-inflammatory diseases. Annals of the Rheumatic Diseases, 2016, 75, 1550-1557.	0.9	57
155	Gene-expression analysis of adult-onset Stillâ€™s disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatric Rheumatology, 2015, 13, 50.	2.1	100
156	Automatic Leak Detection in Buried Plastic Pipes of Water Supply Networks by Means of Vibration Measurements. Shock and Vibration, 2015, 2015, 1-13.	0.6	53
157	Digging deeper for greater precision and more impact in JIA. Nature Reviews Rheumatology, 2015, 11, 70-72.	8.0	2
158	Longâ€Term Safety, Efficacy, and Quality of Life in Patients With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept for Up to Seven Years. Arthritis and Rheumatology, 2015, 67, 2759-2770.	5.6	64
159	HLA-DRB1*11and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15970-15975.	7.1	139
160	Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Annals of the Rheumatic Diseases, 2015, 74, 799-805.	0.9	215
161	Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. Annals of the Rheumatic Diseases, 2015, 74, 2043-2049.	0.9	180
162	Cell stress increases ATP release in NLRP3 inflammasome-mediated autoinflammatory diseases, resulting in cytokine imbalance. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 2835-2840.	7.1	106

#	Article	IF	Citations
163	Dissecting the Heterogeneity of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2015, 42, 994-1001.	2.0	59
164	Static balancing of a parallel kinematics machine with Linear-Delta architecture: theory, design and numerical investigation. Mechanism and Machine Theory, 2015, 90, 128-141.	4.5	34
165	Cytokine profiling at disease onset: support for classification of young antinuclear antibody-positive patients as a separate category of juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2015, 74, 470-472.	0.9	16
166	Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference. Autoimmunity Reviews, 2015, 14, 692-702.	5.8	63
167	Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Annals of the Rheumatic Diseases, 2015, 74, 1110-1117.	0.9	251
168	Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo (2). Journal of the American Society of Nephrology: JASN, 2015, 26, 1905-1924.	6.1	58
169	Macrophage Activation Syndrome. Hematology/Oncology Clinics of North America, 2015, 29, 927-941.	2.2	121
170	EULAR-PReS points to consider for the use of imaging in the diagnosis and management of juvenile idiopathic arthritis in clinical practice. Annals of the Rheumatic Diseases, 2015, 74, 1946-1957.	0.9	112
171	Advances in biomarkers for paediatric rheumatic diseases. Nature Reviews Rheumatology, 2015, 11, 265-275.	8.0	37
172	Glucocorticoids in Juvenile Idiopathic Arthritis. NeuroImmunoModulation, 2015, 22, 112-118.	1.8	13
173	Catchâ€Up Growth During Tocilizumab Therapy for Systemic Juvenile Idiopathic Arthritis: Results From a Phase III Trial. Arthritis and Rheumatology, 2015, 67, 840-848.	5.6	63
174	Successful treatment of subacute constrictive pericarditis with interleukin-1Î² receptor antagonist (anakinra). Clinical and Experimental Rheumatology, 2015, 33, 294-5.	0.8	12
175	Is it worth including subtalar joint in ultrasound ankle assessment of patients with juvenile idiopathic arthritis?. Pediatric Rheumatology, 2014, 12, .	2.1	0
176	Defining Criteria for Disease Activity States in Nonsystemic Juvenile Idiopathic Arthritis Based on a Threeâ€Variable Juvenile Arthritis Disease Activity Score. Arthritis Care and Research, 2014, 66, 1703-1709.	3.4	115
177	Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo. Journal of the American Society of Nephrology: JASN, 2014, 25, 2483-2498.	6.1	112
178	A169: Cumulative Long-Term Safety, Efficacy and Patient-Reported Outcomes in Children With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept: Up to 7 Years of Treatment. Arthritis and Rheumatology, 2014, 66, S218-S219.	5.6	0
179	Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Annals of the Rheumatic Diseases, 2014, 73, 1114-1122.	0.9	106
180	A45: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2014, 66, S67-S68.	5.6	5

#	Article	IF	Citations
181	Validation of the Auto-Inflammatory Diseases Activity Index (AIDAI) for hereditary recurrent fever syndromes. Annals of the Rheumatic Diseases, 2014, 73, 2168-2173.	0.9	120
182	The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Annals of the Rheumatic Diseases, 2014, 73, 2160-2167.	0.9	256
183	A66: Assessment of Radiographic Progression in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2â€Year Results From the TENDER Trial. Arthritis and Rheumatology, 2014, 66, S96.	5.6	2
184	Validation of Relapse Risk Biomarkers for Routine Use in Patients With Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2014, 66, 949-955.	3.4	47
185	A14: Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk in Patients With Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2014, 66, S23-S24.	5.6	5
186	Frequency of Radiographic Damage and Progression in Individual Joints in Children With Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2014, 66, 27-33.	3.4	9
187	Agreement Among Musculoskeletal Pediatric Specialists in the Assessment of Radiographic Joint Damage in Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2014, 66, 34-39.	3.4	3
188	A54: Insulin Sensitivity Is Improved in sJIA Children With Insulin Resistance After Tocilizumab Treatment: Results From the TENDER Study. Arthritis and Rheumatology, 2014, 66, S80-S81.	5.6	4
189	Development of new classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Pediatric Rheumatology, 2014, 12, .	2.1	6
190	Is it worth allowing the presence of morning stiffness in the definition of inactive disease in juvenile idiopathic arthritis?. Pediatric Rheumatology, 2014, 12, .	2.1	0
191	Nearly 20% of children are not correctly classified according to current ilar classification in a PRINTO dataset of more than 12,000 juvenile idiopathic arthritis patients. Pediatric Rheumatology, 2014, 12, .	2.1	0
192	Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis. Annals of the Rheumatic Diseases, 2014, 73, 1083-1090.	0.9	113
193	Osteolytic Lesion in PAPA Syndrome Responding to Anti-interleukin 1 Treatment. Journal of Rheumatology, 2014, 41, 2333-2334.	2.0	28
194	Long-Term Efficacy of Interleukin-1 Receptor Antagonist (Anakinra) in Corticosteroid-Dependent and Colchicine-Resistant Recurrent Pericarditis. Journal of Pediatrics, 2014, 164, 1425-1431.e1.	1.8	94
195	Elastodynamic behavior of balanced closed-loop mechanisms: numerical analysis of a four-bar linkage. Meccanica, 2014, 49, 601-614.	2.0	23
196	Heading Toward a Modern Imaging Approach in Juvenile Idiopathic Arthritis. Current Rheumatology Reports, 2014, 16, 416.	4.7	17
197	Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients. Arthritis and Rheumatology, 2014, 66, 3160-3169.	5.6	322
198	Defining criteria for high disease activity in juvenile idiopathic arthritis based on the Juvenile Arthritis Disease Activity Score. Annals of the Rheumatic Diseases, 2014, 73, 1380-1383.	0.9	77

#	Article	IF	Citations
199	Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. Annals of the Rheumatic Diseases, 2014, 73, 662-667.	0.9	92
200	Glucocorticoids in juvenile idiopathic arthritis. Annals of the New York Academy of Sciences, 2014, 1318, 65-70.	3.8	7
201	Performance of Current Guidelines for Diagnosis of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2014, 66, 2871-2880.	5.6	101
202	Female Sex and Oligoarthritis Category Are Not Risk Factors for Uveitis in Italian Children with Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2014, 41, 1416-1425.	2.0	25
203	Clinical features of childhood granulomatosis with polyangiitis (wegenerâ€™s granulomatosis). Pediatric Rheumatology, 2014, 12, 18.	2.1	85
204	Increased NLRP3-dependent interleukin 1Î² secretion in patients with familial Mediterranean fever: correlation withMEFVgenotype. Annals of the Rheumatic Diseases, 2014, 73, 462-469.	0.9	108
205	Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2014, 73, 401-406.	0.9	23
206	Juvenile idiopathic arthritis and malignancy. Rheumatology, 2014, 53, 968-974.	1.9	32
207	Static Balancing of a Parallel Kinematics Machine With Linear-Delta Architecture. , 2014, , .		0
208	Genetic association with articular damage in patients with juvenile idiopathic arthritis (JIA). Pediatric Rheumatology, 2014, 12, .	2.1	0
209	The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. Arthritis Research and Therapy, 2013, 15, R33.	3.5	52
210	Dependence of Immunoglobulin Class Switch Recombination in B Cells on Vesicular Release of ATP and CD73 Ectonucleotidase Activity. Cell Reports, 2013, 3, 1824-1831.	6.4	72
211	MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2013, 72, 363-368.	0.9	36
212	Paediatric-onset systemic lupus erythematosus. Best Practice and Research in Clinical Rheumatology, 2013, 27, 351-362.	3.3	101
213	Review: Beyond the NLRP3 Inflammasome: Autoinflammatory Diseases Reach Adolescence. Arthritis and Rheumatism, 2013, 65, 1137-1147.	6.7	37
214	Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Annals of the Rheumatic Diseases, 2013, 72, 678-685.	0.9	350
215	Delineating the Role of Multiple Intraarticular Corticosteroid Injections in the Management of Juvenile Idiopathic Arthritis in the Biologic Era. Arthritis Care and Research, 2013, 65, 1112-1120.	3.4	38
216	Methotrexate Therapy May Prevent the Onset of Uveitis in Juvenile Idiopathic Arthritis. Journal of Pediatrics, 2013, 163, 879-884.	1.8	54

#	Article	IF	Citations
217	Notice of redundant publication: Aerobic capacity and disease activity in children, adolescents and young adults with juvenile idiopathic arthritis (JIA). Pediatric Rheumatology, 2013, 11, 2.	2.1	2
218	Advances from clinical trials in juvenile idiopathic arthritis. Nature Reviews Rheumatology, 2013, 9, 557-563.	8.0	39
219	The Central Role of Anti-IL-1 Blockade in the Treatment of Monogenic and Multi-Factorial Autoinflammatory Diseases. Frontiers in Immunology, 2013, 4, 351.	4.8	48
220	Factors Associated with Achievement of Inactive Disease in Children with Juvenile Idiopathic Arthritis Treated with Etanercept. Journal of Rheumatology, 2013, 40, 192-200.	2.0	43
221	Impact of the European paediatric legislation in paediatric rheumatology: past, present and future. Annals of the Rheumatic Diseases, 2013, 72, 1893-1896.	0.9	29
222	Primary red ear syndrome associated with cochleo-vestibular symptomatology: A paediatric case report. Cephalalgia, 2013, 33, 1277-1280.	3.9	5
223	Autophagy contributes to inflammation in patients with TNFR-associated periodic syndrome (TRAPS). Annals of the Rheumatic Diseases, 2013, 72, 1044-1052.	0.9	69
224	The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Annals of the Rheumatic Diseases, 2013, 72, 686-693.	0.9	109
225	Diagnostic potential of hepcidin testing in pediatrics. European Journal of Haematology, 2013, 90, 323-330.	2.2	32
226	Recurrent Pericarditis in Myhre Syndrome. American Journal of Medical Genetics, Part A, 2013, 161, 1164-1166.	1.2	17
227	Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicentre PRINTO study. Annals of the Rheumatic Diseases, 2013, 72, 1503-1509.	0.9	12
228	Elastodynamic Effects of Mass-Balancing: Experimental Investigation of a Four-Bar Linkage. Advances in Mechanical Engineering, 2013, 5, 949457.	1.6	15
229	New autoantibodies and their clinical associations in juvenile myositis - a systematic review. Acta ReumatolÃ³gica Portuguesa, 2013, 38, 234-41.	0.2	5
230	A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2012, 71, 511-517.	0.9	55
231	Ethics bureaucracy: a significant hurdle for collaborative follow-up of drug effectiveness in rare childhood diseases. Archives of Disease in Childhood, 2012, 97, 561-563.	1.9	14
232	Deficient production of IL-1 receptor antagonist and IL-6 coupled to oxidative stress in cryopyrin-associated periodic syndrome monocytes. Annals of the Rheumatic Diseases, 2012, 71, 1577-1581.	0.9	45
233	Clinical impact ofMEFVmutations in children with periodic fever in a prevalent western European Caucasian population. Annals of the Rheumatic Diseases, 2012, 71, 1961-1965.	0.9	65
234	Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study. Annals of the Rheumatic Diseases, 2012, 71, 1991-1997.	0.9	103

#	Article	IF	Citations
235	Parent and Child Acceptable Symptom State in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2012, 39, 856-863.	2.0	72
236	It is time to rethink juvenile idiopathic arthritis classification and nomenclature. Annals of the Rheumatic Diseases, 2012, 71, 1437-1439.	0.9	154
237	Macrophage activation syndrome. Indian Journal of Rheumatology, 2012, 7, 27-35.	0.4	6
238	Novel automated system for magnetic resonance imaging quantification of the inflamed synovial membrane volume in patients with juvenile idiopathic arthritis. Arthritis Care and Research, 2012, 64, 1657-1664.	3.4	15
239	Systemic juvenile idiopathic arthritis. Autoimmunity Reviews, 2012, 12, 56-59.	5.8	118
240	An International registry on Autoinflammatory diseases: the Eurofever experience. Annals of the Rheumatic Diseases, 2012, 71, 1177-1182.	0.9	158
241	Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis. New England Journal of Medicine, 2012, 367, 2396-2406.	27.0	588
242	New takes on categorization and treatment. Nature Reviews Rheumatology, 2012, 8, 67-68.	8.0	8
243	The growth of Pediatric Rheumatology: Pediatric Rheumatology European Society and the impact factor. Pediatric Rheumatology, 2012, 10, 19.	2.1	1
244	Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study. Pediatric Rheumatology, 2012, 10, 39.	2.1	70
245	Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis. New England Journal of Medicine, 2012, 367, 2385-2395.	27.0	716
246	Maladie de Still de lâ€™enfant, Ã©volution conceptuelle et thÃ©rapeutique. Revue Du Rhumatisme Monographies, 2012, 79, 3-6.	0.0	0
247	Joint European League Against Rheumatism and European Renal Associationâ€“European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Annals of the Rheumatic Diseases, 2012, 71, 1771-1782.	0.9	868
248	MRI of the wrist in juvenile idiopathic arthritis: proposal of a paediatric synovitis score by a consensus of an international working group. Results of a multicentre reliability study. Pediatric Radiology, 2012, 42, 1047-1055.	2.0	32
249	Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score. Arthritis and Rheumatism, 2012, 64, 2366-2374.	6.7	171
250	A phase II, multicenter, openâ€label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis and Rheumatism, 2012, 64, 557-567.	6.7	167
251	Toward the Development of New Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. Annals of Paediatric Rheumatology, 2012, 1, 1.	0.0	15
252	Toward a treat-to-target approach in the management of juvenile idiopathic arthritis. Clinical and Experimental Rheumatology, 2012, 30, S157-62.	0.8	34

#	Article	IF	Citations
253	Development and preliminary validation of a paediatric-targeted MRI scoring system for the assessment of disease activity and damage in juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2011, 70, 440-446.	0.9	60
254	An International Consensus Survey of Diagnostic Criteria for Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2011, 38, 764-768.	2.0	140
255	IMMUNOLOGY AND RHEUMATIC DISEASES. , 2011, , 16-52.		1
256	Juvenile idiopathic arthritis. Lancet, The, 2011, 377, 2138-2149.	13.7	638
257	Current Medical Treatments for Juvenile Idiopathic Arthritis. Frontiers in Pharmacology, 2011, 2, 60.	3.5	20
258	Role of IL-1 Beta in the Development of Human TH17 Cells: Lesson from NLPR3 Mutated Patients. PLoS ONE, 2011, 6, e20014.	2.5	105
259	Criteria to define response to therapy in paediatric rheumatic diseases. European Journal of Clinical Pharmacology, 2011, 67, 125-131.	1.9	24
260	A randomized, double-blind, placebo-controlled trial of paracetamol and ketoprofren lysine salt for pain control in children with pharyngotonsillitis cared by family pediatricians. Italian Journal of Pediatrics, 2011, 37, 48.	2.6	15
261	2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care and Research, 2011, 63, 465-482.	3.4	658
262	Development and initial validation of composite parentâ€•and childâ€•centered disease assessment indices for juvenile idiopathic arthritis. Arthritis Care and Research, 2011, 63, 1262-1270.	3.4	27
263	Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician's Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI; SDI). Arthritis Care and Research, 2011, 63, S112-7	3.4	55
264	Antinuclear antibodyâ€"positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. Arthritis and Rheumatism, 2011, 63, 267-275.	6.7	140
265	Clinical presentation and pathogenesis of cold-induced autoinflammatory disease in a family with recurrence of an NLRP12 mutation. Arthritis and Rheumatism, 2011, 63, 830-839.	6.7	162
266	Longâ€•term clinical profile of children with the lowâ€•penetrance R92Q mutation of the TNFRSF1A gene. Arthritis and Rheumatism, 2011, 63, 1141-1150.	6.7	99
267	Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: An international multicenter PRINTO study. Arthritis and Rheumatism, 2011, 63, 3142-3152.	6.7	47
268	Pharmacologic P2X purinergic receptor antagonism in the treatment of collagenâ€•induced arthritis. Arthritis and Rheumatism, 2011, 63, 3323-3332.	6.7	18
269	Emerging drugs to treat juvenile idiopathic arthritis. Expert Opinion on Emerging Drugs, 2011, 16, 493-505.	2.4	22
270	A preliminary score for the assessment of disease activity in hereditary recurrent fevers: results from the AIDAI (Auto-Inflammatory Diseases Activity Index) Consensus Conference. Annals of the Rheumatic Diseases, 2011, 70, 309-314.	0.9	70

#	Article	IF	Citations
271	Candidate Genes in Patients with Autoinflammatory Syndrome Resembling Tumor Necrosis Factor Receptor-associated Periodic Syndrome Without Mutations in the TNFRSF1A Gene. Journal of Rheumatology, 2011, 38, 1378-1384.	2.0	17
272	Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis. Rheumatology, 2011, 50, 1627-1634.	1.9	59
273	HLA-G and HLA-E in patients with juvenile idiopathic arthritis. Rheumatology, 2011, 50, 966-972.	1.9	38
274	JIA, treatment and possible risk of malignancies. Nature Reviews Rheumatology, 2011, 7, 6-7.	8.0	17
275	A New Approach to Clinical Care of Juvenile Idiopathic Arthritis: The Juvenile Arthritis Multidimensional Assessment Report. Journal of Rheumatology, 2011, 38, 938-953.	2.0	159
276	Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO). Archives of Disease in Childhood, 2011, 96, 596-601.	1.9	143
277	Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. Clinical and Experimental Rheumatology, 2011, 29, 117-24.	0.8	34
278	Periodic fever, apthous stomatitis, pharyngitis and adenitis syndrome. Current Opinion in Rheumatology, 2010, 22, 579-584.	4.3	36
279	Treatment of autoinflammatory syndromes. Current Opinion in Pediatrics, 2010, 22, 771-778.	2.0	12
280	Evaluation of 21-Numbered Circle and 10-Centimeter Horizontal Line Visual Analog Scales for Physician and Parent Subjective Ratings in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2010, 37, 1534-1541.	2.0	119
281	Synovial and inflammatory diseases in childhood: role of new imaging modalities in the assessment of patients with juvenile idiopathic arthritis. Pediatric Radiology, 2010, 40, 985-998.	2.0	97
282	Follow-Up and Quality of Life of Patients with Cryopyrin-Associated Periodic Syndromes Treated with Anakinra. Journal of Pediatrics, 2010, 157, 310-315.e1.	1.8	105
283	Longâ€term outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients. Arthritis Care and Research, 2010, 62, 63-72.	3.4	207
284	The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care and Research, 2010, 62, 1533-1541.	3.4	84
285	Abatacept improves healthâ€related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care and Research, 2010, 62, 1542-1551.	3.4	72
286	Longâ€term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis and Rheumatism, 2010, 62, 1792-1802.	6.7	204
287	Interferonâ€Î³â€“dependent inhibition of B cell activation by bone marrowâ€“derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. Arthritis and Rheumatism, 2010, 62, 2776-2786.	6.7	161
288	Is it time to move to active comparator trials in juvenile idiopathic arthritis?: A review of current study designs. Arthritis and Rheumatism, 2010, 62, 3131-3139.	6.7	57

#	Article	IF	Citations
289	The effect of infliximab plus methotrexate on the modulation of inflammatory disease markers in juvenile idiopathic arthritis: analyses from a randomized, placebo-controlled trial. Pediatric Rheumatology, 2010, 8, 24.	2.1	20
290	The Immune Inhibitory Receptor LAIR-1 Is Highly Expressed by Plasmacytoid Dendritic Cells and Acts Complementary with NKp44 to Control IFNÎ± Production. PLoS ONE, 2010, 5, e15080.	2.5	64
291	Methotrexate Withdrawal at 6 vs 12 Months in Juvenile Idiopathic Arthritis in Remission<subtitle>A Randomized Clinical Trial</subtitle>. JAMA - Journal of the American Medical Association, 2010, 303, 1266.	7.4	229
292	Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1Î² secretion. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 9789-9794.	7.1	129
293	Does removal of aids/devices and help make a difference in the Childhood Health Assessment Questionnaire disability index?. Annals of the Rheumatic Diseases, 2010, 69, 82-87.	0.9	11
294	Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Annals of the Rheumatic Diseases, 2010, 69, 718-722.	0.9	129
295	Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial. Annals of the Rheumatic Diseases, 2010, 69, 1479-1483.	0.9	46
296	Homeostatic expansion of autoreactive immunoglobulin-secreting cells in the Rag2 mouse model of Omenn syndrome. Journal of Experimental Medicine, 2010, 207, 1525-1540.	8.5	66
297	Development and Initial Validation of a Radiographic Scoring System for the Hip in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2010, 37, 432-439.	2.0	35
298	A new short and simple health-related quality of life measurement for paediatric rheumatic diseases: initial validation in juvenile idiopathic arthritis. Rheumatology, 2010, 49, 1272-1280.	1.9	39
299	Juvenile idiopathic arthritis: state of the art and future perspectives. Annals of the Rheumatic Diseases, 2010, 69, 1260-1263.	0.9	101
300	Dynamic contrast-enhanced magnetic resonance imaging in the assessment of disease activity in patients with juvenile idiopathic arthritis. Rheumatology, 2010, 49, 178-185.	1.9	69
301	EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation. Annals of the Rheumatic Diseases, 2010, 69, 790-797.	0.9	187
302	EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Annals of the Rheumatic Diseases, 2010, 69, 798-806.	0.9	1,073
303	Agreement between multi-dimensional and renal-specific response criteria in patients with juvenile systemic lupus erythematosus and renal disease. Clinical and Experimental Rheumatology, 2010, 28, 424-33.	0.8	3
304	The Hypoxic Synovial Environment Regulates Expression of Vascular Endothelial Growth Factor and Osteopontin in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2009, 36, 1318-1329.	2.0	31
305	Achievement of a State of Inactive Disease at Least Once in the First 5 Years Predicts Better Outcome of Patients with Polyarticular Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2009, 36, 628-634.	2.0	61
306	Successful treatment of idiopathic recurrent pericarditis in children with interleukinâ€1Î² receptor antagonist (anakinra): An unrecognized autoinflammatory disease?. Arthritis and Rheumatism, 2009, 60, 264-268.	6.7	142

#	Article	IF	Citations
307	Healthâ€related quality of life of patients with juvenile dermatomyositis: Results from the paediatric rheumatology international trials organisation multinational quality of life cohort study. Arthritis and Rheumatism, 2009, 61, 509-517.	6.7	45
308	Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis and Rheumatism, 2009, 61, 658-666.	6.7	579
309	Macrophage activation syndrome in juvenile systemic lupus erythematosus: A multinational multicenter study of thirtyâ€eight patients. Arthritis and Rheumatism, 2009, 60, 3388-3399.	6.7	231
310	The 423Q polymorphism of the Xâ€linked inhibitor of apoptosis gene influences monocyte function and is associated with periodic fever. Arthritis and Rheumatism, 2009, 60, 3476-3484.	6.7	13
311	HRCT and pulmonary function tests in monitoring of lung involvement in juvenile systemic sclerosis. Pediatric Pulmonology, 2009, 44, 1226-1234.	2.0	22
312	Phenotypic and functional characterization of switch memory B cells from patients with oligoarticular juvenile idiopathic arthritis. Arthritis Research and Therapy, 2009, 11, R150.	3.5	44
313	Differentiating PFAPA Syndrome From Monogenic Periodic Fevers. Pediatrics, 2009, 124, e721-e728.	2.1	138
314	Development and Testing of Reduced Joint Counts in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2009, 36, 183-190.	2.0	40
315	Monogenic Autoinflammatory Syndromes. , 2009, , 33-49.		0
316	Diagnosis and Management of Autoinflammatory Diseases in Childhood. Journal of Clinical Immunology, 2008, 28, 73-83.	3.8	90
317	Consensus procedures and their role in pediatric rheumatology. Current Rheumatology Reports, 2008, 10, 142-146.	4.7	44
318	Network in pediatric rheumatology: the example of the Pediatric Rheumatology International Trials Organization. World Journal of Pediatrics, 2008, 4, 186-191.	1.8	5
319	The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/european League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: A prospective validation study. Arthritis and Rheumatism, 2008, 59, 4-13.	6.7	136
320	Performing trials in children with rheumatic diseases: Comment on the editorial by Lehman. Arthritis and Rheumatism, 2008, 58, 1201-1202.	6.7	3
321	The pattern of response to antiâ€"interleukinâ€1 treatment distinguishes two subsets of patients with systemicâ€onset juvenile idiopathic arthritis. Arthritis and Rheumatism, 2008, 58, 1505-1515.	6.7	346
322	Persistent efficacy of anakinra in patients with tumor necrosis factor receptorâ€"associated periodic syndrome. Arthritis and Rheumatism, 2008, 58, 1516-1520.	6.7	297
323	Hypoxic synovial environment and expression of macrophage inflammatory protein 3Î³/CCL20 in juvenile idiopathic arthritis. Arthritis and Rheumatism, 2008, 58, 1833-1838.	6.7	35
324	Validation of the Childhood Health Assessment Questionnaire in active juvenile systemic lupus erythematosus. Arthritis and Rheumatism, 2008, 59, 1112-1119.	6.7	33

#	Article	IF	Citations
325	Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. Arthritis and Rheumatism, 2008, 59, 1120-1127.	6.7	98
326	Assessing current outcomes of juvenile idiopathic arthritis: A crossâ€sectional study in a tertiary center sample. Arthritis and Rheumatism, 2008, 59, 1571-1579.	6.7	52
327	Magnetic resonance imaging, ultrasonography, and conventional radiography in the assessment of bone erosions in juvenile idiopathic arthritis. Arthritis and Rheumatism, 2008, 59, 1764-1772.	6.7	126
328	Bone Marrow-Derived Mesenchymal Stem Cells Induce Both Polyclonal Expansion and Differentiation of B Cells Isolated from Healthy Donors and Systemic Lupus Erythematosus Patients. Stem Cells, 2008, 26, 562-569.	3.2	247
329	Treatment of Takayasu's Arteritis with Tumor Necrosis Factor Antagonists. Journal of Pediatrics, 2008, 153, 432-434.	1.8	49
330	Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet, The, 2008, 372, 383-391.	13.7	486
331	Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis. New England Journal of Medicine, 2008, 359, 810-820.	27.0	530
332	Pediatric Antiphospholipid Syndrome: Clinical and Immunologic Features of 121 Patients in an International Registry. Pediatrics, 2008, 122, e1100-e1107.	2.1	193
333	A longitudinal analysis of physical functional disability over the course of juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2008, 67, 1159-1164.	0.9	34
334	Juvenile idiopathic arthritis. Lancet, The, 2007, 369, 767-778.	13.7	1,426
335	Antiphospholipid Syndrome in Pediatrics. Rheumatic Disease Clinics of North America, 2007, 33, 499-523.	1.9	32
336	Proxy-reported health-related quality of life of patients with juvenile idiopathic arthritis: The pediatric rheumatology international trials organization multinational quality of life cohort study. Arthritis and Rheumatism, 2007, 57, 35-43.	6.7	121
337	Differential recognition of heat-shock protein dnaJâ€"derived epitopes by effector and Treg cells leads to modulation of inflammation in juvenile idiopathic arthritis. Arthritis and Rheumatism, 2007, 56, 1648-1657.	6.7	67
338	Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis. Arthritis and Rheumatism, 2007, 56, 3087-3095.	6.7	80
339	A randomized, placeboâ€controlled trial of infliximab plus methotrexate for the treatment of polyarticularâ€course juvenile rheumatoid arthritis. Arthritis and Rheumatism, 2007, 56, 3096-3106.	6.7	373
340	Pattern of interleukinâ€1Î² secretion in response to lipopolysaccharide and ATP before and after interleukinâ€1 blockade in patients with CIAS1 mutations. Arthritis and Rheumatism, 2007, 56, 3138-3148.	6.7	229
341	Development and validation of a new short and simple measure of physical function for juvenile idiopathic arthritis. Arthritis and Rheumatism, 2007, 57, 913-920.	6.7	95
342	Physicians' and parents' ratings of inactive disease are frequently discordant in juvenile idiopathic arthritis. Journal of Rheumatology, 2007, 34, 1773-6.	2.0	30

#	Article	IF	Citations
343	Neutrophils from patients withTNFRSF1A mutations display resistance to tumor necrosis factorâ€"induced apoptosis: Pathogenetic and clinical implications. Arthritis and Rheumatism, 2006, 54, 998-1008.	6.7	138
344	Level of agreement between children, parents, and physicians in rating pain intensity in juvenile idiopathic arthritis. Arthritis and Rheumatism, 2006, 55, 177-183.	6.7	70
345	The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of the definition of improvement. Arthritis and Rheumatism, 2006, 55, 355-363.	6.7	72
346	A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis and Rheumatism, 2006, 54, 2989-2996.	6.7	133
347	Use of the sharp and larsen scoring methods in the assessment of radiographic progression in juvenile idiopathic arthritis. Arthritis and Rheumatism, 2006, 55, 717-723.	6.7	61
348	Correlation between juvenile idiopathic arthritis activity and damage measures in early, advanced, and longstanding disease. Arthritis and Rheumatism, 2006, 55, 843-849.	6.7	44
349	Clinical assessment in juvenile dermatomyositis. Autoimmunity, 2006, 39, 197-203.	2.6	22
350	Outcome in juvenile onset systemic lupus erythematosus. Current Opinion in Rheumatology, 2005, 17, 568-573.	4.3	77
351	MVK mutations and associated clinical features in Italian patients affected with autoinflammatory disorders and recurrent fever. European Journal of Human Genetics, 2005, 13, 314-320.	2.8	71
352	A randomized, doubleâ€blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: Shortâ€and longâ€term efficacy and safety results. Arthritis and Rheumatism, 2005, 52, 563-572.	6.7	79
353	Patients with antinuclear antibodyâ€"positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthritis and Rheumatism, 2005, 52, 826-832.	6.7	197
354	Targeting the interleukinâ€6 receptor: A new treatment for systemic juvenile idiopathic arthritis?. Arthritis and Rheumatism, 2005, 52, 687-693.	6.7	59
355	Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. Arthritis and Rheumatism, 2005, 52, 2092-2102.	6.7	142
356	The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of the disease activity core set. Arthritis and Rheumatism, 2005, 52, 2854-2864.	6.7	77
357	Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synovia. Journal of Experimental Medicine, 2005, 201, 1793-1803.	8.5	332
358	Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Journal of Pediatrics, 2005, 146, 598-604.	1.8	365
359	Course of joint disease in patients with antinuclear antibody-positive juvenile idiopathic arthritis. Journal of Rheumatology, 2005, 32, 1805-10.	2.0	28
360	A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis and Rheumatism, 2004, 50, 2191-2201.	6.7	307

#	Article	IF	Citations
361	Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. Arthritis and Rheumatism, 2004, 51, 458-464.	6.7	93
362	Phenotypic and functional characterisation of CCR7+ and CCR7- CD4+ memory T cells homing to the joints in juvenile idiopathic arthritis. Arthritis Research, 2004, 7, R256.	2.0	56
363	International research networks in pediatric rheumatology: the PRINTO perspective. Current Opinion in Rheumatology, 2004, 16, 566-570.	4.3	87
364	Functional and prognostic relevance of the âˆ’173 polymorphism of the macrophage migration inhibitory factor gene in systemicâ€onset juvenile idiopathic arthritis. Arthritis and Rheumatism, 2003, 48, 1398-1407.	6.7	173
365	Positive family history of psoriasis does not affect the clinical expression and course of juvenile idiopathic arthritis patients with oligoarthritis. Arthritis and Rheumatism, 2003, 49, 488-493.	6.7	27
366	Assessment of damage in juvenile-onset systemic lupus erythematosus: A multicenter cohort study. Arthritis and Rheumatism, 2003, 49, 501-507.	6.7	150
367	Prognostic factors for radiographic progression, radiographic damage, and disability in juvenile idiopathic arthritis. Arthritis and Rheumatism, 2003, 48, 3509-3517.	6.7	93
368	Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. British Journal of Rheumatology, 2003, 42, 1452-1459.	2.3	209
369	Are the number of joints involved or the presence of psoriasis still useful tools to identify homogeneous disease entities in juvenile idiopathic arthritis?. Journal of Rheumatology, 2003, 30, 1900-3.	2.0	77
370	Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. Arthritis and Rheumatism, 2002, 46, 232-237.	6.7	67
371	Proinflammatory responses to self HLA epitopes are triggered by molecular mimicry to Epstein-Barr virus proteins in oligoarticular juvenile idiopathic arthritis. Arthritis and Rheumatism, 2002, 46, 2721-2729.	6.7	66
372	Effect of IL-6 on IGF Binding Protein-3: A Study in IL-6 Transgenic Mice and in Patients with Systemic Juvenile Idiopathic Arthritis. Endocrinology, 2001, 142, 4818-4826.	2.8	147
373	Nephroticâ€range proteinuria, the major risk factor for early atherosclerosis in juvenileâ€onset systemic lupus erythematosus. Arthritis and Rheumatism, 2000, 43, 1405-1409.	6.7	103
374	Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis. Arthritis and Rheumatism, 1999, 42, 807-811.	6.7	71
375	The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis. Journal of Pediatrics, 1999, 135, 316-320.	1.8	57
376	Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. Journal of Pediatrics, 1998, 133, 262-265.	1.8	58
377	Cytokines in juvenile rheumatoid arthritis. Current Opinion in Rheumatology, 1997, 9, 428-433.	4.3	44
378	The Clinical Significance of Antiphospholipid Antibodies. Annals of Medicine, 1997, 29, 159-163.	3.8	27

#	Article	IF	Citations
379	Preliminary definition of improvement in juvenile arthritis. Arthritis and Rheumatism, 1997, 40, 1202-1209.	6.7	40
380	Preliminary definition of improvement in juvenile arthritis. Arthritis and Rheumatism, 1997, 40, 1202-1209.	6.7	922
381	Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. Journal of Pediatrics, 1996, 128, 275-278.	1.8	134
382	Positive selection in autoimmunity: Abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis. Nature Medicine, 1995, 1, 448-452.	30.7	168
383	Correlation of Serum Interleukinâ€6 Levels with Joint Involvement and Thrombocytosis in Systemic Juvenile Rheumatoid Arthritis. Arthritis and Rheumatism, 1991, 34, 1158-1163.	6.7	325
384	Asymmetric Marfan syndrome. American Journal of Medical Genetics Part A, 1988, 30, 905-909.	2.4	21
385	Systemic lupus erythematosus with jaccoud's arthropathy mimicking juvenile rheumatoid arthritis. Arthritis and Rheumatism, 1987, 30, 1062-1064.	6.7	29
386	Activity of Classical and Alternative Pathways of Complement in Preterm and Small for Gestational Age Infants. Pediatric Research, 1984, 18, 281-285.	2.3	75